KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Deferred Revenue (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Current Deferred Revenue for 9 consecutive years, with $967000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 14.27% to $967000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $967000.0 through Dec 2025, down 14.27% year-over-year, with the annual reading at $967000.0 for FY2025, 14.27% down from the prior year.
  • Current Deferred Revenue hit $967000.0 in Q4 2025 for Bionano Genomics, down from $1.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q3 2024 to a low of $301000.0 in Q1 2021.
  • Historically, Current Deferred Revenue has averaged $925550.0 across 5 years, with a median of $999000.0 in 2023.
  • Biggest five-year swings in Current Deferred Revenue: soared 267.77% in 2022 and later dropped 17.12% in 2023.
  • Year by year, Current Deferred Revenue stood at $684000.0 in 2021, then rose by 27.34% to $871000.0 in 2022, then decreased by 10.1% to $783000.0 in 2023, then soared by 44.06% to $1.1 million in 2024, then dropped by 14.27% to $967000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for BNGO at $967000.0 in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.